{"component": "definition", "props": {"groups": [{"samples": [{"hash": "ecJXhyDOMzC", "uri": "/contracts/ecJXhyDOMzC#linker", "label": "National Main Collective Agreement", "score": 32.2672265608, "published": true}, {"hash": "fnTAoo5F1ea", "uri": "/contracts/fnTAoo5F1ea#linker", "label": "National Main Collective Agreement", "score": 31.4979583922, "published": true}, {"hash": "ljWpYqog0C0", "uri": "/contracts/ljWpYqog0C0#linker", "label": "National Main Collective Agreement", "score": 27.5996029754, "published": true}], "snippet_links": [{"key": "an-employee-who", "type": "clause", "offset": [6, 21]}, {"key": "engaged-in", "type": "definition", "offset": [25, 35]}], "snippet": "means an employee who is engaged in operating a linking machine for toe-closing of stockings or socks or for joining parts of fully fashioned garments or attaching trimmings to fully fashioned garments or parts of garments;", "size": 39, "hash": "df71989b0ca27503a440c8f56b59ccab", "id": 1}, {"samples": [{"hash": "p5qWyl3sbb", "uri": "/contracts/p5qWyl3sbb#linker", "label": "National Main Collective Agreement", "score": 33.2672265608, "published": true}, {"hash": "4h6UIsBmOye", "uri": "/contracts/4h6UIsBmOye#linker", "label": "National Main Collective Agreement", "score": 33.2672265608, "published": true}, {"hash": "dDPi6RVKlfB", "uri": "/contracts/dDPi6RVKlfB#linker", "label": "National Main Collective Agreement", "score": 32.4979583922, "published": true}], "snippet_links": [{"key": "an-employee", "type": "definition", "offset": [6, 17]}, {"key": "engaged-in", "type": "definition", "offset": [18, 28]}], "snippet": "means an employee engaged in operating a linking machine;", "size": 22, "hash": "fdb2fae85830a8b743cc308571b91f47", "id": 2}, {"samples": [{"hash": "Jckfm8G6w", "uri": "/contracts/Jckfm8G6w#linker", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.749486653, "published": true}, {"hash": "hTHrx0EV42k", "uri": "/contracts/hTHrx0EV42k#linker", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385352498, "published": true}, {"hash": "6aFf4JTjPSh", "uri": "/contracts/6aFf4JTjPSh#linker", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.711156742, "published": true}], "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [106, 124]}, {"key": "cytotoxic-compound", "type": "definition", "offset": [128, 146]}, {"key": "form-a", "type": "clause", "offset": [244, 250]}], "snippet": "means any compound or composition that is useful for linking a cytotoxic or cytostatic moiety, including, without limitation, a Cytotoxic Compound, and a cell-binding moiety, including, without limitation, an Antibody or a Probody, together to form a conjugate of the cytotoxic or cytostatic moiety with the cell-binding moiety.", "size": 8, "hash": "6f95359024dd1a456116b008fa51367b", "id": 3}, {"samples": [{"hash": "42EgtxIghRS", "uri": "/contracts/42EgtxIghRS#linker", "label": "Discovery Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 29.5961670089, "published": true}, {"hash": "iin8hiIQlX", "uri": "/contracts/iin8hiIQlX#linker", "label": "Co Development and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.5872689938, "published": true}, {"hash": "2sL5mf496j6", "uri": "/contracts/2sL5mf496j6#linker", "label": "Discovery Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.5872689938, "published": true}], "snippet_links": [], "snippet": "means a compound or other substance used to link a Payload to an Antibody or Probody.", "size": 6, "hash": "7e2a58cca37feac293a462f1d9cf2dcb", "id": 4}, {"samples": [{"hash": "1BJtetMK7tv", "uri": "/contracts/1BJtetMK7tv#linker", "label": "Collaboration and License Agreement (ADC Therapeutics SA)", "score": 32.2087611225, "published": true}, {"hash": "aDY1eiQCCiP", "uri": "/contracts/aDY1eiQCCiP#linker", "label": "License Agreement (ADC Therapeutics SA)", "score": 31.3107460643, "published": true}, {"hash": "d9HkaMCfDV5", "uri": "/contracts/d9HkaMCfDV5#linker", "label": "License Agreement (ADC Therapeutics SA)", "score": 31.1656399726, "published": true}], "snippet_links": [], "snippet": "means [**].", "size": 6, "hash": "d625c0c2cdb17b208fba7a69b82dd049", "id": 5}, {"samples": [{"hash": "jpnZcbP2zYu", "uri": "/contracts/jpnZcbP2zYu#linker", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446269678, "published": true}, {"hash": "ggnshgntmlA", "uri": "/contracts/ggnshgntmlA#linker", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.749486653, "published": true}, {"hash": "lgwM84kDb46", "uri": "/contracts/lgwM84kDb46#linker", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385352498, "published": true}], "snippet_links": [], "snippet": "means a moiety or means used to conjugate a Payload to an Antibody or Probody.", "size": 5, "hash": "262df24ea07188d70e6b87873449d416", "id": 6}, {"samples": [{"hash": "bUQDjISpoCv", "uri": "/contracts/bUQDjISpoCv#linker", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 34.3497604381, "published": true}, {"hash": "bHKMWrplZc7", "uri": "/contracts/bHKMWrplZc7#linker", "label": "Collaboration and Commercial License Agreement", "score": 31.340862423, "published": true}, {"hash": "df0ANPdsiJb", "uri": "/contracts/df0ANPdsiJb#linker", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 28.4140999316, "published": true}], "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [14, 31]}], "snippet": "is defined in the definition of Mersana Platform Know-How.", "size": 4, "hash": "2712d1517239c7a569e830918b10bb63", "id": 7}, {"samples": [{"hash": "gKH6Rukubqs", "uri": "/contracts/gKH6Rukubqs#linker", "label": "Option, License, and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "eAharHezhsr", "uri": "/contracts/eAharHezhsr#linker", "label": "Option, License, and Collaboration Agreement (Arvinas Holding Company, LLC)", "score": 29.7008898015, "published": true}, {"hash": "q4N0M9Xkus", "uri": "/contracts/q4N0M9Xkus#linker", "label": "Option, License, and Collaboration Agreement (Arvinas Holding Company, LLC)", "score": 29.6598220397, "published": true}], "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [14, 31]}], "snippet": "is defined in the definition of PROTAC.", "size": 4, "hash": "b15bde6073d8b6b17bbef1565803ada4", "id": 8}, {"samples": [{"hash": "zoftSHBapV", "uri": "/contracts/zoftSHBapV#linker", "label": "Collaboration and Option Agreement (Immunogen Inc)", "score": 28.8548939083, "published": true}, {"hash": "gY7FylzczcR", "uri": "https://immunogen.gcs-web.com/static-files/ed8e84bf-aa08-4690-a318-e2dd11db3430", "label": "immunogen.gcs-web.com", "score": 14.8228818356, "published": false}, {"hash": "j7WHyaVMCKF", "uri": "https://investor.immunogen.com/static-files/ed8e84bf-aa08-4690-a318-e2dd11db3430", "label": "investor.immunogen.com", "score": 9.1752224504, "published": false}], "snippet_links": [{"key": "agreement-to", "type": "clause", "offset": [51, 63]}, {"key": "cytotoxic-compound", "type": "definition", "offset": [116, 134]}, {"key": "form-a", "type": "clause", "offset": [163, 169]}], "snippet": "means any compound or composition [***] under this Agreement to, or [***] under this Agreement as useful to, link a Cytotoxic Compound and an Antibody together to form a conjugate of such Cytotoxic Compound with the Antibody.", "size": 4, "hash": "adde2ba0e291c55738916d1e22be7dbb", "id": 9}, {"samples": [{"hash": "cAj5n7Kdiql", "uri": "/contracts/cAj5n7Kdiql#linker", "label": "Collaboration and License Agreement (Immunogen Inc)", "score": 25.6543463381, "published": true}, {"hash": "jGx2a99MfMZ", "uri": "/contracts/jGx2a99MfMZ#linker", "label": "Collaboration and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}, {"hash": "5RRmD7MoZRs", "uri": "https://investor.immunogen.com/static-files/56daf4ad-71ea-4eb7-8cc7-95132df88727", "label": "investor.immunogen.com", "score": 14.7207131219, "published": false}], "snippet_links": [], "snippet": "means any chemical entity utilized to attach an Effector Molecule to a TAP Antibody.", "size": 3, "hash": "094492169ab253a82b43c856800b3c2e", "id": 10}], "next_curs": "ClMSTWoVc35sYXdpbnNpZGVyY29udHJhY3Rzci8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIPbGlua2VyIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Linker", "snippet": "means an employee who is engaged in operating a linking machine for toe-closing of stockings or socks or for joining parts of fully fashioned garments or attaching trimmings to fully fashioned garments or parts of garments;", "size": 149, "id": "linker", "examples": ["Enzon\u2019s product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized <strong>Linker</strong> TechnologyTM PEGylation platform that utilizes customized <strong>linkers</strong> designed to release compounds at a controlled rate.", "For the avoidance of doubt, MedImmune will not exclusively license PBD or <strong>Linker</strong> Chemistry in a manner that would effectively prevent Licensee from exercising its rights under ARTICLE 2 of this Agreement as described above.", "Further, Enzon will have the opportunity to explore the potential for added benefit with its next-generation PEGylation Customized <strong>Linker</strong> Technology.", "It is understood and agreed by the Parties that each Party shall be free to exploit, without obligation to any other Party, any <strong>Linker</strong> Technology that is not included within the definition of an Ambrx Technology Invention and is not otherwise proprietary to the other Party (for example, included within the other Party\u2019s know-how or patent rights that are not licensed under or pursuant to this Agreement).", "ADCT reserves all rights not specifically granted under this Agreement, including but not limited to ADCT\u2019s rights to any PBD and/or <strong>Linker</strong> that is not part of an ADC.", "In case ADCT, after having made a Withdrawal pursuant to Article 8, decides to [**] any Patents within the ADCT Intellectual Property covering the <strong>Linker</strong> and/or the PBD or other technology used in the ADC, then ADCT shall promptly so notify Genmab (which notice shall be at least [**] days before any relevant deadline for such patent right).", "Any new Patent arising from the activities under the Pre-Clinical Work Plan or Clinical Work Plan directed to the PBD or <strong>Linker</strong> or other technology used in the ADC shall be deemed Spirogen Intellectual Property or ADCT Intellectual Property, as applicable, and included in the license grants hereunder.", "To the extent that enforcement actions concern Spirogen Intellectual Property relating to the PBD or <strong>Linker</strong> or other technology used in the ADC, ADCT shall use Commercially Reasonable Efforts to consult Genmab with regard to [**].", "The conversion utility srec (see Figure 1-1) can be used to convert the executable file from the COFF <strong>Linker</strong> to a suitable format for PROM burning.", "The product containing such new drug payload or <strong>Linker</strong> shall be deemed to be a Product for purposes of this Agreement."], "related": [["clinker", "Clinker", "Clinker"], ["cyanoacrylate-adhesive", "Cyanoacrylate adhesive", "Cyanoacrylate adhesive"], ["anaerobic-digester", "Anaerobic digester", "Anaerobic digester"], ["stratum", "Stratum", "Stratum"], ["tetrahydrocannabinol", "Tetrahydrocannabinol", "Tetrahydrocannabinol"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}